Ryzneuta Side Effects

Generic name: efbemalenograstim alfa

Medically reviewed by Drugs.com. Last updated on Sep 10, 2024.

Note: This document provides detailed information about Ryzneuta.

Applies to efbemalenograstim alfa: parenteral injection for sub-q use Side Effects associated with efbemalenograstim alfa. Some dosage forms listed on this page may not apply specifically to the brand name Ryzneuta.

Applies to efbemalenograstim alfa: parenteral injection for sub-q use.

Side effects include:

Adverse effects reported in ≥10% of patients receiving efbemelanograstim alfa-vuxw include nausea, anemia, and thrombocytopenia.

For healthcare professionals

Applies to efbemalenograstim alfa: subcutaneous solution.

General adverse events

The most common adverse reactions with a frequency of 10% or greater were nausea, anemia, thrombocytopenia, fatigue, and bone pain.^[Ref]

Cardiovascular

• Frequency not reported: Capillary leak syndrome, aortitis

Hematologic

• Very common (10% or more): Anemia (up to 12%), thrombocytopenia (up to 10%)
• Frequency not reported: Sickle cell crisis, leukocytosis

Hypersensitivity

• Frequency not reported: Serious allergic reactions

Oncologic

• Frequency not reported: Myelodysplastic syndrome, acute myeloid leukemia

Other

• Frequency not reported: Splenic rupture

Respiratory

• Frequency not reported: Acute respiratory distress syndrome

Genitourinary

• Very common (10% or more): Nausea (up to 42%)

Renal

• Frequency not reported: Glomerulonephritis

See also:

Further information

Ryzneuta side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.

Medical Disclaimer